National Physical Laboratories (NPL)

NPL has developed and patented a novel approach for a sensitive immuno assay platform which generates a digital read out.

The technique is quantitative, highly sensitive, and can use less refined samples such as whole blood. This technology can bring significant advantages in POC, microbiology and other immuno assay products.

NPL is seeking to understand the requirements of those who may be interested in future licensing in order to inform its development of the technology.